Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Uterine Cervical Neoplasms 2Prostatic Neoplasms 2Vaginal Neoplasms 1Sarcoma, Ewing 1Carcinosarcoma 1Breast Neoplasms 1Biochemically Recurrent Prostate Carcinoma 1

Interventions

Cyclophosphamide 5regorafenib 3Temozolomide 3Magnetic Resonance Spectroscopy 3Irinotecan 3Etoposide 3Doxorubicin 3ulixertinib 2tipifarnib 2selpercatinib 2palbociclib 2ivosidenib 2etoposide phosphate 2cabozantinib 2X-Rays 2Vincristine 2Specimen Handling 2Sirolimus 2Radiation 2Phantoms, Imaging 2Nuclear Medicine Department, Hospital 2Ifosfamide 2Biopsy 2tazemetostat 1racemetyrosine 1pembrolizumab 1olaparib 1larotrectinib 1ganitumab 1erdafitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Sarcoma, Ewing × Congresses as Topic × Clear all
NCT02306161 2026-06-03

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
312 enrolled 14 charts
Sarcoma

Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡